Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?

OBJECTIVE: This study evaluated the characteristics of new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) in clinical practice to assess the applicability of the findings from clinical trials (Empagliflozin, Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Shih-Chieh, Lin, Yi-Han, Chang, Kai-Cheng, Chan, Yuk-Ying, Hung, Ming-Jui, Kao Yang, Yea-Huei, Lai, Edward Chia-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Epidemiology/Health Services Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954814/
https://www.ncbi.nlm.nih.gov/pubmed/32043472
http://dx.doi.org/10.1136/bmjdrc-2019-000742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954814/
https://www.ncbi.nlm.nih.gov/pubmed/32043472
http://dx.doi.org/10.1136/bmjdrc-2019-000742

Ejemplares similares